EIF2AK3 and cancer: These results are consistent with previous findings that PERK signaling in cancer contributes to adaptive pathways rather than to cancer cell death, as demonstrated by the fact that pharmacologic inhibition of PERK attenuates tumor growth (Wang et al., 2017, 2019; Bagratuni et al., 2020).